Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/lapatinib-in-combination-with-paclitaxel-plays-synergistic-antitumor-W9bGqydqeR
References (43)
-
L. McHugh, A. Sayan, Jakob Mejlvang, T. Griffiths, Yiyang Sun, M. Manson, E. Tulchinsky, J. Mellon, M. Kriajevska (2009)
Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.International journal of oncology, 34 4
-
Kensuke Shiraishi, K. Mimura, S. Izawa, A. Inoue, Shugo Shiba, T. Maruyama, Mitsuaki Watanabe, Y. Kawaguchi, M. Inoue, H. Fujii, K. Kono (2013)
Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicityGastric Cancer, 16
-
Xiao-fang Guo, Xiao-fei Zhu, Gen-shen Zhong, B. Deng, Zhitao Gao, Hui Wang (2012)
Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.Oncology reports, 27 5
-
L. Gibault, J. Metges, V. Conan-Charlet, P. Lozac'h, M. Robaszkiewicz, C. Bessaguet, N. Lagarde, A. Volant (2005)
Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancerBritish Journal of Cancer, 93
-
T. Dragovich, S. McCoy, C. Fenoglio-Preiser, Jiang Wang, J. Benedetti, A. Baker, C. Hackett, S. Urba, K. Zaner, C. Blanke, J. Abbruzzese (2006)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 30
-
N. Ando, T. Iizuka, H. Ide, K. Ishida, M. Shinoda, T. Nishimaki, W. Takiyama, Hiroshi Watanabe, K. Isono, N. Aoyama, H. Makuuchi, O. Tanaka, H. Yamana, S. Ikeuchi, T. Kabuto, K. Nagai, Y. Shimada, Y. Kinjo, H. Fukuda (2003)
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 24
-
D. Ilson (2008)
Esophageal cancer chemotherapy: recent advances.Gastrointestinal cancer research : GCR, 2 2
-
Thomas Holbro, G. Civenni, N. Hynes (2003)
The ErbB receptors and their role in cancer progression.Experimental cell research, 284 1
-
C. Fitzmaurice, D. Dicker, A. Pain, Hannah Hamavid, M. Moradi-Lakeh, Michael MacIntyre, Christine Allen, Gillian Hansen, Rachel Woodbrook, C. Wolfe, R. Hamadeh, A. Moore, A. Werdecker, Bradford Gessner, Braden Ao, B. McMahon, C. Karimkhani, Chuanhua Yu, Graham Cooke, D. Schwebel, David Carpenter, David Pereira, D. Nash, Dhruv Kazi, D. Leo, D. Plass, K. Ukwaja, George Thurston, Kim Jin, Edgar Simard, E. Mills, Eun‐Kee Park, F. Catalá-López, G. deVeber, C. Gotay, G. Khan, H. Hosgood, I. Santos, J. Leasher, J. Singh, J. Leigh, J. Jonas, J. Sanabria, J. Beardsley, K. Jacobsen, Ken Takahashi, R. Franklin, L. Ronfani, M. Montico, L. Naldi, M. Tonelli, J. Geleijnse, M. Petzold, M. Shrime, M. Younis, N. Yonemoto, N. Breitborde, P. Yip, F. Pourmalek, P. Lotufo, A. Esteghamati, G. Hankey, R. Ali, R. Lunevicius, R. Malekzadeh, R. Dellavalle, R. Weintraub, R. Lucas, R. Hay, D. Rojas-Rueda, R. Westerman, S. Sepanlou, Sandra Nolte, S. Patten, S. Weichenthal, S. Abera, S. Fereshtehnejad, I. Shiue, T. Driscoll, T. Vasankari, U. Alsharif, V. Rahimi-Movaghar, V. Vlassov, W. Marcenes, W. Mekonnen, Y. Melaku, Y. Yano, A. Artaman, I. Campos, J. MacLachlan, U. Mueller, Daniel Kim, Matias Trillini, B. Eshrati, Hywel Williams, K. Shibuya, R. Dandona, Kinnari Murthy, B. Cowie, Azmeraw Amare, C. Antonio, C. Castañeda-Orjuela, C. Gool, F. Violante, I. Oh, K. Deribe, K. Søreide, L. Knibbs, M. Kereselidze, M. Green, Rosario Cárdenas, N. Roy, T. Tillmann, Yongmei Li, H. Krueger, L. Monasta, Subhojit Dey, S. Sheikhbahaei, N. Hafezi-Nejad, G. Kumar, C. Sreeramareddy, L. Dandona, Haidong Wang, S. Vollset, A. Mokdad, Joshua Salomon, R. Lozano, T. Vos, M. Forouzanfar, Alan Lopez, C. Murray, M. Naghavi (2015)
The Global Burden of Cancer 2013.JAMA oncology, 1 4
-
T. Powles, R. Huddart, T. Elliott, S. Sarker, C. Ackerman, Robert Jones, S. Hussain, S. Crabb, S. Jagdev, J. Chester, S. Hilman, M. Beresford, G. Macdonald, S. Santhanam, J. Frew, A. Stockdale, S. Hughes, D. Berney, S. Chowdhury (2017)
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 1
-
H. Imai, K. Komine, Shin Takahashi, K. Saijo, Yoshinari Okada, Akihiro Kobayashi, A. Okita, S. Chikamatsu, Y. Kasahara, M. Takahashi, Takayuki Oishi, H. Shirota, Masanobu Takahashi, H. Shimodaira, C. Ishioka (2016)
Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell CarcinomaChemotherapy, 61
-
Norio Kondo, M. Tsukuda, Yukari Ishiguro, Machiko Kimura, K. Fujita, Atsuko Sakakibara, Hideaki Takahashi, G. Toth, H. Matsuda (2010)
Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.Oncology reports, 23 4
-
Y. Liu, Z. Ren, Long Yuan, Shuning Xu, Z. Yao, L. Qiao, Ke Li (2016)
Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer.American journal of cancer research, 6 10
-
An-hui Wang, Yuan Liu, Bo Wang, Yi-Xuan He, Ye-Xian Fang, Yong-ping Yan (2014)
Epidemiological studies of esophageal cancer in the era of genome-wide association studies.World journal of gastrointestinal pathophysiology, 5 3
-
F. Cappuzzo, M. Varella-Garcia, H. Shigematsu, I. Domenichini, S. Bartolini, G. Ceresoli, E. Rossi, V. Ludovini, V. Gregorc, L. Toschi, W. Franklin, L. Crinò, A. Gazdar, P. Bunn, F. Hirsch (2005)
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 22
-
M. Kavallaris (2010)
Microtubules and resistance to tubulin-binding agentsNature Reviews Cancer, 10
-
B. Bystricky, A. Okines, D. Cunningham (2011)
Optimal Therapeutic Strategies for Resectable Oesophageal or Oesophagogastric Junction CancerDrugs, 71
-
S. Lorenzen, Jorge Knorrenschild, G. Haag, M. Pohl, P. Thuss-Patience, F. Bassermann, U. Helbig, F. Weissinger, E. Schnoy, K. Becker, G. Stocker, J. Rüschoff, A. Eisenmenger, I. Karapanagiotou-Schenkel, F. Lordick (2015)
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.European journal of cancer, 51 5
-
Charles Geyer, J. Forster, D. Lindquist, Stephen Chan, C. Romieu, T. Pieńkowski, A. Jagiełło-Gruszfeld, J. Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, M. Campone, Neville Davidson, Mark Berger, C. Oliva, S. Rubin, S. Stein, David Cameron (2006)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.The New England journal of medicine, 355 26
-
A. Ohtsu, M. Shah, E. Cutsem, S. Rha, A. Sawaki, Sook Park, Ho Lim, Y. Yamada, Jian Wu, B. Langer, M. Starnawski, Yoon-Koo Kang (2011)
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 30
-
H. Gómez, D. Doval, M. Chavez, P. Ang, Z. Aziz, S. Nag, C. Ng, S. Franco, L. Chow, M. Arbushites, M. Casey, M. Berger, S. Stein, G. Sledge (2008)
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 18
-
J. Hecht, Y. Bang, S. Qin, H. Chung, Jianming Xu, Joon-Oh Park, K. Jeziorski, Y. Shparyk, P. Hoff, A. Sobrero, P. Salman, Jin Li, S. Protsenko, Z. Wainberg, M. Buyse, K. Afenjar, V. Houé, Agathe Garcia, Tomomi Kaneko, Yingjie Huang, S. Khan-Wasti, S. Santillana, M. Press, D. Slamon (2016)
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 5
-
G. Tomasello, M. Ghidini, S. Barni, R. Passalacqua, F. Petrelli (2017)
Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancerExpert Review of Clinical Pharmacology, 10
-
M. Polee, F. Eskens, M. Burg, T. Splinter, PD Siersema, HW Tilanus, J. Verweij, G. Stoter, A. Gaast (2002)
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancerBritish Journal of Cancer, 86
-
Wenmin Hou, Xia Qin, Xuehua Zhu, Maogui Fei, Ping Liu, Li Liu, Hanlim Moon, Pingkuan Zhang, J. Greshock, K. Bachman, B. Ye, Hui Wang, Crystal Zang (2013)
Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.Oncology reports, 30 2
-
E. Kwak, J. Jankowski, S. Thayer, G. Lauwers, Brian Brannigan, Patricia Harris, R. Okimoto, Sara Haserlat, David Driscoll, D. Ferry, B. Muir, J. Settleman, C. Fuchs, M. Kulke, D. Ryan, Jeffrey Clark, D. Sgroi, D. Haber, D. Bell (2006)
Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic AdenocarcinomasClinical Cancer Research, 12
-
J. Tanizaki, I. Okamoto, K. Takezawa, S. Tsukioka, J. Uchida, M. Kiniwa, M. Fukuoka, K. Nakagawa (2010)
Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with HER2 AmplificationMolecular Cancer Therapeutics, 9
-
Ken Kato, M. Tahara, S. Hironaka, K. Muro, H. Takiuchi, Y. Hamamoto, H. Imamoto, Norihito Amano, T. Seriu (2011)
A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapyCancer Chemotherapy and Pharmacology, 67
-
Y. Bang, E. Cutsem, A. Feyereislova, H. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, Julie Hill, M. Lehle, J. Rüschoff, Yoon-Koo Kang (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 376
-
Yan Guo, W. Fu, Hong Chen, C. Shang, M. Zhong (2011)
miR-24 functions as a tumor suppressor in Hep2 laryngeal carcinoma cells partly through down-regulation of the S100A8 proteinOncology Reports, 27
-
D. Reddy, Z. Wainberg (2011)
Targeted Therapies for Metastatic Esophagogastric CancerCurrent Treatment Options in Oncology, 12
-
T. Chou, P. Talalay (1984)
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.Advances in enzyme regulation, 22
-
C. Mariette, G. Piessen, J. Triboulet (2007)
Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities.The Lancet. Oncology, 8 6
-
T. Brien, R. Odze, Christine Sheehan, B. Mckenna, J. Ross (2000)
HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma.Human pathology, 31 1
-
G. Neuner, A. Patel, M. Suntharalingam (2009)
Chemoradiotherapy for esophageal cancer.Gastrointestinal cancer research : GCR, 3 2
-
R. Tishler, P. Schiff, C. Geard, E. Hall (1992)
Taxol: a novel radiation sensitizer.International journal of radiation oncology, biology, physics, 22 3
-
L. McHugh, M. Kriajevska, J. Mellon, T. Griffiths (2007)
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.Urology, 69 2
-
J. Ajani, D. Ilson, K. Daugherty, R. Pazdur, P. Lynch, D. Kelsen (1994)
Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus.Journal of the National Cancer Institute, 86 14
-
M. Suntharalingam, K. Winter, D. Ilson, A. Dicker, L. Kachnic, A. Konski, A. Chakravarthy, C. Anker, H. Thakrar, N. Horiba, N. Horiba, A. Dubey, J. Greenberger, A. Raben, J. Giguere, K. Roof, G. Videtic, J. Pollock, H. Safran, C. Crane, C. Crane (2017)
Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical TrialJAMA Oncology, 3
-
Z. Wainberg, A. Anghel, Amrita Desai, Raul Ayala, Tong Luo, Brent Safran, M. Fejzo, J. Hecht, D. Slamon, R. Finn, Corresponding Author (2010)
Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivoClinical Cancer Research, 16
-
M. Arnal, Á. Arenas, Á. Arbeloa (2015)
Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries.World journal of gastroenterology, 21 26
-
闵先军, Lagergren Jesper, Lagergren Pernilla (2011)
Oesophageal cancerBMJ, 14
-
A. Okines, D. Cunningham, I. Chau (2011)
Targeting the human EGFR family in esophagogastric cancerNature Reviews Clinical Oncology, 8
- Publisher
- Springer Journals
- Copyright
- Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
- Subject
- Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
- ISSN
- 0344-5704
- eISSN
- 1432-0843
- DOI
- 10.1007/s00280-018-3627-3
- Publisher site
- See Article on Publisher Site
Abstract
Purpose Paclitaxel-based chemoradiotherapy was proven to be efficacious in treating patients with advanced esophageal cancer. However, the toxicity and the development of resistance limited its anticancer efficiency. The present study was to evaluate the antitumor effects of lapatinib, a dual tyrosine inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), combined with paclitaxel on the esophageal squamous cancer. Methods MTT assays were used to evaluate the effects of the combination of lapatinib and paclitaxel on the growth of esophageal squamous cancer cell lines (KYSE150, KYSE450, KYSE510 and TE-7). The activity of the combination of two agents on cell invasion, migration and apoptosis was measured by wound healing assay, transwell assay and Annexin V-FITC/PI stain assay. Western blot assay was used to analyze the effects of the two agents on the EGFR/HER2 signaling. The in vivo efficacy was evaluated in KYSE450 xenograft nude mouse model. Results The combination of lapatinib and paclitaxel was highly synergistic in inhibiting cell growth with a combination index of < 1, and suppressed significantly the invasion and migration capability of esophageal squamous cancer cells. Esophageal squamous cancer cells displayed increased rates of apoptosis after treatment with lapatinib plus paclitaxel.
Journal
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Jun 16, 2018